Prime-boost strategy could avoid HCV standard of care for Transgene, ChronTech and Inovio
This article was originally published in Scrip
Executive Summary
Transgene is collaborating with ChronTech Pharma and Inovio Pharmaceuticals to conduct a Phase I trial to test a 'prime and boost' strategy involving the companies' hepatitis C virus (HCV) vaccines which are under separate development on their own.